AAPL347.96+3.97 (+1.15%) ▲|ABBV284.63-0.17 (-0.06%) ▼|ABT102.52+2.01 (+2.00%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.60+3.96 (+2.23%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.07+1.46 (+0.45%) ▲|BA187.53-4.75 (-2.47%) ▼|BAC51.10+0.32 (+0.63%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.54-12.06 (-1.05%) ▼|BMY63.01+1.89 (+3.09%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B547.00+8.01 (+1.49%) ▲|C122.56-1.29 (-1.04%) ▼|CAT703.84-36.38 (-4.91%) ▼|CL97.40+4.00 (+4.28%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.44-3.22 (-1.56%) ▼|COP145.64-0.03 (-0.02%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.24+8.46 (+3.50%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.49+1.71 (+1.84%) ▲|CVX226.65-0.13 (-0.06%) ▼|DE643.60+7.06 (+1.11%) ▲|DHR229.88-3.98 (-1.70%) ▼|DIS113.14+1.31 (+1.17%) ▲|DUK125.42+4.75 (+3.94%) ▲|EMR160.26-2.85 (-1.75%) ▼|FDX303.99+5.76 (+1.93%) ▲|GD350.76+6.05 (+1.75%) ▲|GE293.51-2.37 (-0.80%) ▼|GEV827.38-98.55 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.22+1.11 (+1.46%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.27-13.45 (-1.49%) ▼|HD327.66+13.52 (+4.30%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.19+0.73 (+0.29%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.68+9.90 (+3.84%) ▲|JPM336.51+1.32 (+0.39%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.74+35.99 (+2.83%) ▲|LMT590.20+38.69 (+7.01%) ▲|LOW204.39+7.83 (+3.98%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA632.81+10.19 (+1.64%) ▲|MCD252.55+6.30 (+2.56%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.58+3.55 (+3.82%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.54+0.80 (+0.46%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.25-2.63 (-1.75%) ▼|MS183.94-3.08 (-1.64%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.91+3.63 (+4.64%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.31+0.78 (+2.08%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.52-3.62 (-2.80%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.41+0.56 (+1.88%) ▲|PG165.60+8.76 (+5.59%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.76+4.30 (+2.18%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.55-17.47 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL347.96+3.97 (+1.15%) ▲|ABBV284.63-0.17 (-0.06%) ▼|ABT102.52+2.01 (+2.00%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.60+3.96 (+2.23%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.07+1.46 (+0.45%) ▲|BA187.53-4.75 (-2.47%) ▼|BAC51.10+0.32 (+0.63%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.54-12.06 (-1.05%) ▼|BMY63.01+1.89 (+3.09%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B547.00+8.01 (+1.49%) ▲|C122.56-1.29 (-1.04%) ▼|CAT703.84-36.38 (-4.91%) ▼|CL97.40+4.00 (+4.28%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.44-3.22 (-1.56%) ▼|COP145.64-0.03 (-0.02%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.24+8.46 (+3.50%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.49+1.71 (+1.84%) ▲|CVX226.65-0.13 (-0.06%) ▼|DE643.60+7.06 (+1.11%) ▲|DHR229.88-3.98 (-1.70%) ▼|DIS113.14+1.31 (+1.17%) ▲|DUK125.42+4.75 (+3.94%) ▲|EMR160.26-2.85 (-1.75%) ▼|FDX303.99+5.76 (+1.93%) ▲|GD350.76+6.05 (+1.75%) ▲|GE293.51-2.37 (-0.80%) ▼|GEV827.38-98.55 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.22+1.11 (+1.46%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.27-13.45 (-1.49%) ▼|HD327.66+13.52 (+4.30%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.19+0.73 (+0.29%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.68+9.90 (+3.84%) ▲|JPM336.51+1.32 (+0.39%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.74+35.99 (+2.83%) ▲|LMT590.20+38.69 (+7.01%) ▲|LOW204.39+7.83 (+3.98%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA632.81+10.19 (+1.64%) ▲|MCD252.55+6.30 (+2.56%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.58+3.55 (+3.82%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.54+0.80 (+0.46%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.25-2.63 (-1.75%) ▼|MS183.94-3.08 (-1.64%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.91+3.63 (+4.64%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.31+0.78 (+2.08%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.52-3.62 (-2.80%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.41+0.56 (+1.88%) ▲|PG165.60+8.76 (+5.59%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.76+4.30 (+2.18%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.55-17.47 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
19.5 C
New York
Thursday, October 22, 2026

Tag: therapies

newsFORsourcecompanycontentinformation1releasesmarket

RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma

Research Published in NEJM Evidence and presented at the International Conference on Malignant Lymphoma NEW BRUNSWICK, N.J. and BOSTON, June 19, 2025 /PRNewswire/ -- Researchers from...

Birch Allergy Market Forecast Report 2025-2035: Innovations in Immunotherapy Transforming Birch Allergy Treatment

The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and improved healthcare infrastructures in key regions such as the U.S., U.K., and Germany drive market expansion. Key therapies, including antihistamines and sublingual immunotherapy, are evolving alongside biologics and targeted treatments for severe cases. Despite challenges like high costs and regulatory hurdles, strategic partnerships and R&D in biologics are shaping the market. Ongoing innovations and digital health integrations are set to enhance patient outcomes globally. 
The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and improved healthcare infrastructures in key regions such as the U.S., U.K., and Germany drive market expansion. Key therapies, including antihistamines and sublingual immunotherapy, are evolving alongside biologics and targeted treatments for severe cases. Despite challenges like high costs and regulatory hurdles, strategic partnerships and R&D in biologics are shaping the market. Ongoing innovations and digital health integrations are set to enhance patient outcomes globally.

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromesbe...

Happy Ring Earns Second FDA Clearance–Now Approved for At-Home Sleep Testing to Simplify the Diagnosis and Treatment of Sleep Apnea and Related Health Conditions

First FDA-cleared smart ring for multi-night sleep testing and 24/7 biometrics — to catch disease early—years before standard care. AUSTIN, Texas, June 19, 2025 /PRNewswire/...

Theranica to Present Three Real-World Evidence Studies at AHS Scientific Meeting Highlighting the Impact of the Nerivio® REN Wearable on Migraine Treatment

Theranica is presenting three real-world evidence studies at the American Headache Society (AHS) 67th Annual Scientific Congress.

RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, June 19, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies...

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has...

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and EuropeSEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced...

Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the current developmental pipeline for osteoarthritis is robust, with several companies initiating clinical trials to investigate new treatment options or...

BrightSpring Health Services Announces Onco360® Selected as National Pharmacy Partner for Multiple New Cancer and Rare Disease Drugs

LOUISVILLE, Ky., June 18, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud to announce that its specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders.

Nuvalent Appoints Christy Oliger to Board of Directors

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,...

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with...

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

Catalyst Clinical Research Wins the Excellence in Clinical Trial Management Award

Fierce CRO Awards acknowledge the company's focus to deliver for our customers  WILMINGTON, N.C., June 18, 2025 /PRNewswire/ -- Catalyst Clinical Research today proudly announces it...

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®

The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers